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Abstract
We aimed to evaluate the association of albuminuria and estimated glomerular filtration rate (eGFR) at baseline and changes
in these parameters with left ventricular mass index (LVMI) at 7 years in adults with hypertension from communities in
Pakistan. A nested cohort of 539 hypertensives aged 40 years and older from a community-living population in Karachi,
Pakistan, followed up for 7 years in the Control of Blood Pressure and Risk Attenuation trial. Urine spot albumin-to-
creatinine ratio (UACR) and serum creatinine-based eGFR were assessed at baseline and 7 years, and echocardiography
at 7 years. Mean age of participants was 50.9  9.1 (standard deviation) years; 63% were female. Mean eGFR was
91.0  15.9 (standard deviation) mL/min/1.73 m2 and median (interquartile range) UACR 6.2 (3.9, 11.3) mg/g. In multivar-
iate analysis, although baseline eGFR was marginally associated with LVMI, a strong association was found between higher
LVMI with greater rate of decline in eGFR (b ¼ 1.05; 95% confidence interval [CI]: [1.94, 0.17]). Higher baseline
UACR was significantly associated with higher follow-up LVMI (b ¼ 2.26; 95% CI: [0.87, 3.65]), as was rate of UACR in-
crease of 1.07 mg/g/y versus of <0.14 mg/g/y. (b ¼ 4.19; 95% CI: [0.75, 7.63]). Associations with developing left ven-
tricular hypertrophy were found for reduced baseline eGFR, higher baseline UACR, and greater rate of UACR increase,
but not for rate of eGFR decline. Comparable results were observed for the outcomes of posterior wall thickness and septal
wall thickness. Higher baseline albuminuria, lower baseline eGFR, and their longitudinal worsening were significantly asso-
ciated with higher LVMI or the development of left ventricular hypertrophy among individuals with hypertension in Pakistan.
J Am Soc Hypertens 2017;11(12):811–822.  2017 The Authors. Published by Elsevier Inc. on behalf of American Society
of Hypertension. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Keywords: Creatinine; glomerular filtration rate; left ventricular hypertrophy.
Introduction
Higher left ventricular mass index (LVMI) or left ven-
tricular hypertrophy (LVH) is indicative of hypertensive
target organ damage and is predictive of future cardiovascu-
lar morbidity and mortality.1,2 Kidney dysfunction, mani-
fested as reduced estimated glomerular filtration rate
(eGFR)3 or as albuminuria,4 is also a marker of hyperten-
sive target organ damage and is independently associated
with mortality and increased risk of cardiovascular
event.4–6 In addition, LVH and kidney dysfunction often
coexist, as has been shown in cross-sectional studies.7,8
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Longitudinal data are limited and suggest a bidirectional
relationship between kidney dysfunction and LV mass.
Higher baseline LVMI has been associated with lower
eGFR and LVH with rapid decline in eGFR.9,10 More
recently, studies in individuals without advanced kidney
disease showed that lower baseline eGFR and rapid decline
in eGFR predicted higher future LVMI.11 Furthermore,
baseline albuminuria and change in albuminuria have
been shown to be predictive of LVH regression12,13 and
greater left ventricular mass (LVM).14 However, the com-
bined impact of dynamic changes in both eGFR and albu-
minuria on LVM has not been reported.
The South Asian population is known to be at high risk
for cardiovascular disease (CVD) and kidney disease, and
related premature mortality.15,16 However, studies in South
Asians evaluating the association between kidney dysfunc-
tion and LVM are scarce, with existing reports limited
largely to whites or African-American populations.17
We conducted a prospective study in a nested cohort of
539 individuals with hypertension from the general popula-
tion in Karachi, Pakistan, with an average follow-up of
7 years, as part of the Control of Blood Pressure and
Risk Attenuation (COBRA) trial.18 We assessed the associ-
ation of baseline eGFR, change in eGFR, and baseline albu-
minuria and change in albuminuria, and their combined
effect on LV mass after 7 years of follow-up. We hypothe-
sized that in hypertensive adults from the general popula-
tion in Karachi, reduced eGFR, and/or increased
albuminuria at baseline or their worsening during follow-
up, is each independently associated with higher LVM, in-
dependent of other risk factors.
Methods
Study Population
We conducted a post hoc analysis of data from the CO-
BRA trial, a cluster randomized controlled trial of hyper-
tensive individuals in communities of Karachi, Pakistan,
between 2004 and 2014.18 Details regarding recruitment
procedures have been published elsewhere.18 Briefly, 12
geographic census-based clusters were selected using a
multistage random sampling technique. In order to examine
the intervention effect, a 2  2 factorial design was used to
randomly assign three clusters to four study groups: home
health education, general practitioner training, home health
education and general practitioner combined, and no inter-
vention. Participants were chosen by door-to-door visits
within each of the 12 clusters. Eligible participants were
residents of selected clusters, aged 40 year and older with
known hypertension or consistently elevated blood pressure
(BP) on 2 of 3 visits (mean of 2 of 3 measurements of sys-
tolic BP 140 mm Hg or diastolic BP 90 mm Hg). Exclu-
sion criteria were pregnancy or severe mental or physical
disability. The Aga Khan University Ethics Review
Committee granted ethical approval, and informed consent
was obtained from each participant.
Screening and Recruitment
Trained research staff visited all households in each of
the 12 clusters and screened all eligible adults aged 40 years
or older for hypertension after obtaining informed consent.
All recruited participants underwent routine medical
history taking, physical examination, and laboratory assess-
ment. Baseline measurements were obtained in 2004–2005.
A standardized questionnaire was administered to collect
information on age, gender, education, smoking, self-
reported antihypertensive use, history of diabetes, and his-
tory of heart disease. Body mass index (weight [kg]/height2
[meter]2) was calculated, and BP was measured three times
in the sitting position. Mean values of the last two BP read-
ings taken were used for analysis.
As previously described, serum creatinine measurements
were calibrated at the Cleveland Clinic reference laboratory
where serum creatinine levels were measured using the
Roche enzymatic creatinine assay (in duplicate) which is
traceable to the National Institute of Standards and Tech-
nology creatinine reference measurement.19 Glomerular
filtration rate was estimated at baseline and end of study us-
ing the CKD-EPI (CKD Epidemiology Collaboration)
Pakistan (CKD-EPI_PK) equation, a modified version of
CKD-EPI creatinine-based equation with a correction fac-
tor (0.686  CKD-EPI1.059) for South Asians. eGFR
based on this equation denoted eGFR CKD-EPI(PK).
This equation has been validated in the local population
and performs better than the original CKD-EPI equation.19
Urine albumin excretion was measured by nephelometry
using the Array Systems method on a Beckman Coulter,
and creatinine (Synchron Cx-7/Delta) was measured from
a morning spot urine sample. Albuminuria was evaluated
by urine albumin-to-creatinine ratio (UACR).
Follow-up at 7 Years
Trained outcomes assessors visited the homes of the par-
ticipants 7 years after recruitment (2012–2014) to collect
follow-up data. Informed consent was obtained for partici-
pation in the study. BP was measured, and fasting blood
and urine samples were collected using the same protocol
as at baseline. BP change was calculated as follow-up BP
minus baseline BP. Participants were scheduled for an
echocardiogram at the central health facility.
Echocardiographic Data
The echocardiographic examination was carried out us-
ing the portable Philips CX50 imaging system by a trained
sonographer using standardized procedures and rigorous
quality assurance. All results were reviewed by a trained
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cardiologist. Left ventricular measurements were made us-
ing M-mode (MM) and two-dimensional (2D) echo from
the parasternal long axis, adhering to American Society
of Echocardiography guidelines.20 As in the LIFE Study,21
end-diastolic left ventricular septal and posterior wall thick-
ness (PWT) and internal dimensions were used to calculate
LVM using the formula: LVM ¼ 1.04  0.8 ([left ventric-
ular wall thicknesses þ internal dimension]  [internal
dimension]) þ 0.6 g. LVMI was calculated as LVM (based
on MM measurements) in grams divided by body surface
area in square meters. Two trained sonographers performed
all imaging for the study. Interrater reliability among
sonographers for LVMI was very good, with kappa ¼ 0.93.
Analysis
The primary outcome was LVMI, and the secondary
outcome was LVH defined as LVMI greater than 88 g/m2
in females and greater than 102 g/m2 in males.22
The ancillary outcomes of PWT at end diastole and
septal wall thickness (SWT) at end diastole were also
analyzed.
Besides baseline eGFR and baseline UACR, the main
exposure variables were (1) rate of decline in eGFR defined
as the difference between follow-up and baseline eGFR
divided by study duration in years and (2) rate of increase
in albuminuria defined as the difference between follow-
up and baseline UACR divided by study duration in years.
A categorical variable was created using UACR tertile.
Statistical Analysis
Baseline characteristics together with rate of decline in
eGFR and increase in UACR as well as change in systolic
blood pressure (SBP) and diastolic blood pressure (DBP)
were summarized as mean and standard deviation or me-
dian and interquartile range for continuous variables and
as counts and percentage for categorical variables. Compar-
isons between groups with and without LVH were conduct-
ed using the 2-sample t-test for normally distributed
continuous variables and a chi-square test for categorical
variables. The Mann–Whitney U test was used to compare
groups for nonnormal continuous variables. The bivariate
correlations between SBP change and kidney biomarkers
were evaluated using Pearson correlation coefficient or
analysis of variance, where appropriate.
Associations between follow-up LVMI and the markers
eGFR and UACR unadjusted and adjusted for potential
confounders were investigated using linear regression anal-
ysis. Six models were developed by systematically select-
ing variables from a candidate set and introducing them
into the models:
 Model 1: Baseline eGFR; baseline UACR (model 1
for each variable)
 Model 2: Baseline eGFR þ baseline UACR
 Model 3: Variables in model 2 þ age, gender, educa-
tion, BMI, diabetes, heart disease, SBP, DBP, smok-
ing, low-density lipoproteins (LDLs), high-density
lipoproteins, triglyceride, angiotensin-converting
enzyme inhibitor or angiotensin II receptor blocker
use, calcium channel blocker use, b-blocker use, di-
uretics use, and intervention group.
 Model 4: Variables in model 3 þ SBP change, DBP
change, and rate of decline in eGFR
 Model 5: Variables in model 3 þ SBP change, DBP
change, and rate of increase in UACR
 Model 6: Variables in model 3 þ SBP change, DBP
change, rate of increase in UACR, and rate of decline
in eGFR
Using the same model building approach, we performed
logistic regression to determine whether the two markers
were independently associated with follow-up LVH. In
addition, both PWT and SWT were analyzed in model 6.
We log-transformed UACR in all analyses given its right-
skewed distribution. We explored interaction effects of kid-
ney biomarkers with age, gender, SBP change, and DBP
change in multiple linear regression analysis. We also con-
ducted a sensitivity analysis on model 6 by restricting the
analysis to individuals without heart disease. All analyses
accounted for clustering by household at the census level
as a random effect using the SAS GLIMMIX procedure.
Sensitivity analyses were performed using 2D measure-
ments for LVMI. A two-sided P value of .05 was consid-
ered statistically significant. Statistical analyses were
performed using SAS, version 9.4 (SAS Institute, Inc,
Cary, NC).
Results
Study Population
Of all the original 1341 trial participants, 311 individuals
died, 198 migrated, and 92 were lost to follow-up, resulting
in 740 in the 7-year follow-up posttrial follow-up study. Of
the 740, 169 (22.8%) did not undergo echocardiograms for
either refusals or failure to keep appointment, and 571 had
echocardiographic data. From among the latter, we
excluded 26 (1.9%) with no baseline or follow-up serum
creatinine, urine albumin or urine creatinine, three missing
parameters for LVMI, three missing information on heart
disease, 10 missing LDL, high-density lipoprotein, and tri-
glyceride, as well as one missing follow-up DBP, leaving
539 (40% of the original cohort and 73% of those at
7-year follow-up) individuals for analysis.
Compared to the excluded individuals from the original
cohort (n ¼ 802), those analyzed (n ¼ 539) were younger
and had higher education levels and lower rates of diabetes,
heart disease, and smoking. They also had higher baseline
BMI and eGFR, but lower baseline SBP and baseline
UACR (Table S1).
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Themean age among the 539 hypertensives included in the
analysis was 50.9 9.1 years, 63%were female and 34% had
no formal education (Table1).MeanLVMIwas69.9 17.5g/m2,
mean eGFR 91.0  15.9 mL/min/1.73 m2, and median
UACR (interquartile range) 6.2 (3.9, 11.3) mg/g.
Among men, participants with LVH had lower levels of
LDL, higher SBP change, and higher rate of UACR in-
crease than those without LVH. Among women, partici-
pants with LVH were characterized by older age, higher
waist circumference, higher baseline SBP, lower baseline
eGFR, higher baseline UACR, higher SBP increase, and
higher rate of UACR increase than those without LVH
(Tables 1 and 2). There were significant bivariate associa-
tions of change in SBP over 7 years with baseline UACR
(r ¼ 0.12, P ¼ .005), rate of UACR increase
(F2,536 ¼ 3.46, P ¼ .032), and rate of eGFR decline
(r ¼ 0.12, P ¼ .007), each.
Left Ventricular Mass Index
Table 3 shows the association of baseline, rate of decline
in eGFR, and rate of increase in UACR with LVMI at
7 years. In the univariate model (model 1), each 1 mL/
min/1.73 m2 decrease in baseline eGFR was significantly
associated with a 0.21 g/m2 increase in LVMI, and per
unit increase in log-transformed UACR (about 2.7 times
greater in UACR) was predictive of 2.87 g/m2 higher
LVMI. These associations were attenuated but remained
statistically significant when both markers (baseline eGFR
and baseline UACR) were introduced together in model
2. With further adjustment for demographic variables and
other confounders in models 3, 4, and 5, statistical signifi-
cance persisted only for baseline UACR. Rate of decline in
eGFR and increase in UACR were significantly associated
with LVMI in models 4 and 5. After adjustment for rate of
Table 1
Baseline characteristics by left ventricular hypertrophy (LVH) among the hypertensive participants (n ¼ 539)
Variables Total Male Female
No LVH
(n ¼ 185)
LVH
(n ¼ 14)
P Value No LVH
(n ¼ 298)
LVH
(n ¼ 42)
P Value
Age, mean (SD) 50.9 (9.1) 51.2 (8.5) 53.4 (10.6) .37 49.9 (9.0) 56.8 (9.2) <.001
Education, n (%) 1.00 .78
Formal 358 (66.4) 161 (87.0) 12 (85.7) 163 (54.7) 22 (52.4)
Not formal 181 (33.6) 24 (13.0) 2 (14.3) 135 (45.3) 20 (47.6)
Waist circumference (cm) 93.1 (11.0) 96.1 (10.2) 92.7 (15.0) .42 91.0 (10.9) 94.6 (10.9) .043
SBP (mm Hg, mean, SD) 149.1 (22.6) 149.4 (20.7) 142.9 (16.8) .25 147.8 (23.6) 158.8 (22.9) .005
DBP (mm Hg, mean, SD) 92.9 (12.3) 93.4 (12.4) 89.6 (13.5) .26 92.7 (12.3) 92.9 (11.0) .89
Antihypertensive use, n (%) 205 (38.0) 62 (33.5) 2 (14.3) .23 119 (39.9) 22 (52.4) .13
ARB or ACEI, n (%) 71 (13.2) 24 (13.0) 0 (0.0) .23 39 (13.1) 8 (19.1) .29
b-Blocker, n (%) 119 (22.1) 39 (21.1) 2 (14.3) .74 64 (21.5) 14 (33.3) .087
CCB, n (%) 51 (9.5) 13 (7.0) 1 (7.1) 1.00 33 (11.1) 4 (9.5) 1.00
Diuretics, n (%) 12 (2.2) 3 (1.6) 0 (0.0) 1.00 7 (2.4) 2 (4.8) .31
Diabetes, n (%) 129 (23.9) 32 (17.3) 5 (35.7) .14 80 (26.9) 12 (28.6) .81
Heart disease, n (%) 64 (11.9) 21 (11.4) 2 (14.3) .67 38 (12.8) 3 (7.1) .30
Smoking, n (%) .10 .81
Never 333 (61.8) 82 (44.3) 3 (21.4) 218 (73.2) 30 (71.4)
Current or past 206 (38.2) 103 (55.7) 11 (78.6) 80 (26.9) 12 (28.6)
LDL (mg/dL, mean, SD) 120.4 (32.9) 118.1 (31.9) 100.2 (25.2) .042 122.0 (34.0) 126.3 (29.0) .44
HDL (mg/dL, mean, SD) 40.3 (10.3) 36.3 (7.3) 39.0 (8.6) .19 42.7 (11.1) 41.6 (11.1) .55
Triglyceride (mg/dL, mean, SD) 179.4 (102.0) 192.8 (125.8) 191.5 (130.9) .68 168.8 (80.6) 191.9 (105.7) .42
eGFR (mL/min/1.73 m2, mean,
SD)
91.0 (15.9) 86.4 (14.9) 75.4 (26.8) .12 95.5 (13.5) 84.3 (19.4) <.001
UACR (mg/g, median, IQR) 6.2 (3.9, 11.3) 4.9 (3.1, 8.1) 8.2 (3.7, 13.8) .18 6.6 (4.3, 11.8) 9.6 (6.1, 29.3) .003
Intervention group, n (%) .17 .79
No intervention 137 (25.4) 49 (26.5) 3 (21.4) 77 (25.8) 8 (19.1)
GP only 107 (19.9) 40 (21.6) 6 (42.9) 53 (17.8) 8 (19.1)
HHE only 129 (23.9) 44 (23.8) 4 (28.6) 71 (23.8) 10 (23.8)
GP and HHE 166 (30.8) 52 (28.1) 1 (7.1) 97 (32.6) 16 (38.1)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; DBP, diastolic
blood pressure; eGFR, estimated glomerular filtration rate; GP, general practitioner; HDL, high-density lipoprotein; HHE, home health ed-
ucation; IQR, interquartile range; LDL, low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation; UACR, urine albu-
min to creatinine ratio.
Mann–Whitney U test for UACR, LVH was defined as LVMI > 88 g/m2 for women, >102 g/m2 for man.
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Table 2
Change in blood pressure and renal function by left ventricular hypertrophy (LVH) among the hypertensive participants (n ¼ 539)*
Variables Total Male Female
No LVH (n ¼ 185) LVH (n ¼ 14) P Value No LVH (n ¼ 298) LVH (n ¼ 42) P Value
SBP change (mm Hg) .032 .026
Mean, SD 0.1 (24.1) 0.8 (21.1) 13.8 (29.0) 2.3 (24.9) 6.9 (26.9)
Median, IQR 2 (15.5, 15.5) 2.0 (11.0, 15.0) 8.8 (5.0, 32.0) 0 (17.5, 13.5) 9.3 (6.0, 20.5)
DBP change (mm Hg) .081 .53
Mean, SD 6.3 (14.2) 5.7 (13.0) 0.7 (14.8) 7.1 (14.7) 5.6 (15.6)
Median, IQR 6.0 (14.0, 3.5) 5.0 (14.0, 3.5) 0.5 (15.0, 13.5) 6.0 (15.0, 2.0) 4.0 (14.0, 7.0)
Rate of decline in eGFR (mL/min/1.73 m2/y)y .15 .38
Mean, SD 0.3 (1.8) 0.2 (1.3) 0.3 (1.8) 0.4 (1.9) 0.8 (2.4)
Median, IQR 0.0 (0.8, 0.7) 0.1 (0.6, 0.8) 0.1 (0.7, 1.4) 0.0 (1.3, 0.7) 0 (2.7, 0.7)
Rate of increase in UACR (mg/g/y, median, IQR)z 0.5 (0.0, 1.6) 0.3 (0.0, 1.5) 1.3 (0.4, 5.0) .040 0.5 (0.0, 1.5) 1.2 (0.1, 4.1) .045
Rate of increase in UACR (mg/g/y) .16 .01
<0.14 179 (33.2) 71 (38.4) 2 (14.3) 96 (32.2) 10 (23.8)
0.14–1.07 178 (33.0) 55 (29.7) 5 (35.7) 109 (36.6) 9 (21.4)
1.07 182 (33.8) 59 (31.9) 7 (50.0) 93 (31.2) 23 (54.8)
DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; IQR, interquartile range; LVMI, left ventricular mass index; SBP, systolic blood pressure; SD, standard
deviation; UACR, urine albumin-to-creatinine ratio.
Mann–Whitney U test for rate of increase in UACR, LVH was defined as LVMI > 88 g/m2 for women, >102 g/m2 for men.
*Change in blood pressure was calculated using blood pressure at year 7 minus baseline blood pressure.
yRate of decline in eGFR ¼ (eGFR at year 7  eGFR at baseline)/duration of follow up (in y).
zRate of increase in UACR ¼ (UACR at year 7  UACR at baseline)/duration of follow up (in y).
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Table 3
Association of baseline and rate of increase in eGFR (mL/min/1.73 m2) and UACR (mg/g) with LVMI (g/m2) (n ¼ 539) from multiple regression analysis
Variables Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
b-Coefficient
(95% CI)
P Value b-Coefficient
(95% CI)
P
Value
b-Coefficient
(95% CI)
P
Value
b-Coefficient
(95% CI)
P
Value
b-Coefficient
(95% CI)
P
Value
b-Coefficient
(95% CI)
P
Value
Baseline eGFR 0.21
(0.30, 0.12)
<.001 0.18
(0.28, 0.09)
<.001 0.07
(0.19, 0.05)
.23 0.11
(0.23, 0.01)
.06 0.08 (0.19, 0.04) .18 0.11 (0.23, 0.00) .06
Baseline UACR 2.87
(1.55, 4.18)
<.001 2.51
(1.20, 3.82)
<.001 2.08
(0.72, 3.45)
.003 2.00
(0.68, 3.32)
.003 2.31 (0.92, 3.72) .001 2.26 (0.87, 3.65) .002
Gender (female) 1.35
(5.03, 2.34)
.47 1.02
(4.57, 2.54)
.57 0.93 (4.49, 2.63) .61 1.23 (4.78, 2.33) .50
Waist circumference 0.16
(0.02, 0.30)
.027 0.18
(0.05, 0.32)
.009 0.18 (0.04, 0.31) .01 0.18 (0.04, 0.32) .01
Baseline SBP 0.16
(0.06, 0.27)
.003 0.30
(0.18, 0.41)
<.001 0.29 (0.18, 0.40) <.001 0.29 (0.18, 0.40) <.001
SBP change* 0.26
(0.16, 0.35)
<.001 0.24 (0.14, 0.34) <.001 0.25 (0.15, 0.35) <.001
Rate of decline in
eGFRy
1.15
(2.03, 0.28)
.010 1.05 (1.94, 0.17) .02
Rate of increase in
UACRz
.03 .04
<0.14 (Ref) 1.00 1.00
0.14–1.07 2.56 (1.07, 6.19) .17 2.65 (0.97, 6.27) .15
1.07 4.61 (1.18, 8.05) .009 4.19 (0.75, 7.63) .02
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CI, confidence interval; DBP, diastolic blood pressure;
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVMI, left ventricular mass index; SBP, systolic blood pressure;
UACR, urine albumin-to-creatinine ratio.
Model 1: Baseline eGFR, baseline UACR (model 1 for each variable).
Model 2: Baseline eGFR þ baseline UACR.
Model 3: Variables in model 2 þ age, gender, education, waist circumference, diabetes, heart disease, SBP, DBP, smoking, LDL, HDL, triglyceride, ACEI or ARB use, CCB use,
b-blocker use, diuretics use, and intervention group.
Model 4: Variables in model 3 þ SBP change, DBP change, and rate of decline in eGFR.
Model 5: Variables in model 3 þ SBP change, DBP change, and rate of increase in UACR.
Model 6: Variables in model 3 þ SBP change, DBP change, rate of increase in UACR, and rate of decline in eGFR.
All models accounted for clustering effect by household as a random effect.
In addition to kidney function biomarkers and gender, variables with P value < .05 in model 6 were reported in the table.
* Change in SBP was calculated using SBP at year 7 minus baseline SBP.
yRate of decline in eGFR ¼ (eGFR at year 7  eGFR at baseline)/duration of follow-up (in y).
zRate of increase in UACR ¼ (UACR at year 7  UACR at baseline)/duration of follow-up (in y).
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Table 4
Association of baseline and rate of increase in eGFR (mL/min/1.73 m2) and UACR (mg/g) with LVH from logistic regression analysis (n ¼ 539)
Variables Model 1 Model 2 Model 3 Model 4 Model 5 Model 6
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
Baseline eGFR 0.97 (0.95, 0.98) <.001 0.97 (0.96, 0.99) <.001 0.97 (0.95, 0.99) .01 0.97 (0.95, 0.99) .004 0.97 (0.95, 0.99) .01 0.97 (0.95, 0.99) .006
Baseline UACR 1.44 (1.17, 1.76) <.001 1.32 (1.06, 1.63) .01 1.28 (1.01, 1.63) .04 1.30 (1.01, 1.67) .04 1.39 (1.05, 1.83) .02 1.37 (1.04, 1.80) .03
Gender (female) 3.09 (1.34, 7.14) .008 3.43 (1.42, 8.31) .006 3.45 (1.43, 8.32) .006 3.29 (1.36, 7.96) .008
Baseline SBP 1.01 (0.99-1.04) .18 1.03 (1.01, 1.06) .006 1.03 (1.01, 1.06) .01 1.03 (1.01, 1.06) .01
SBP change* 1.03 (1.01, 1.05) .001 1.03 (1.01, 1.05) .004 1.03 (1.01, 1.05) .003
Rate of decline
in eGFRy
0.87 (0.73, 1.02) .10 0.89 (0.75, 1.06) .19
Rate of increase
in UACRz
.11 .17
<0.14 1.00 1.00
0.14–1.07 1.65 (0.64, 4.25) .30 1.64 (0.64, 4.23) .31
1.07 2.33 (1.06, 5.14) .04 2.17 (0.97, 4.83) .06
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CI, confidence interval; DBP, diastolic blood pressure;
eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVH, left ventricular hypertrophy; OR, odds ratio; SBP, systolic blood
pressure; UACR, urine albumin-to-creatinine ratio.
Model 1: Baseline eGFR; baseline UACR (model 1 for each variable).
Model 2: Baseline eGFR þ baseline UACR.
Model 3: Variables in model 2 þ age, gender, education, waist circumference, diabetes, heart disease, SBP, DBP, smoking, LDL, HDL, triglyceride, ACEI or ARB use, CCB use,
b-blocker use, diuretics use, and intervention group.
Model 4: Variables in model 3 þ SBP change, DBP change, and rate of decline in eGFR.
Model 5: Variables in model 3 þ SBP change, DBP change, and rate of increase in UACR.
Model 6: Variables in model 3 þ SBP change, DBP change, rate of increase in UACR, and rate of decline in eGFR.
All models accounted for clustering effect by household as a random effect.
In addition to kidney function biomarkers, variables with P value < .05 in model 6 were reported.
* Change in SBP was calculated using SBP at year 7 minus baseline SBP.
yRate of decline in eGFR ¼ (eGFR at year 7  eGFR at baseline)/duration of follow-up (in y).
zRate of increase in UACR ¼ (UACR at year 7  UACR at baseline)/duration of follow-up (in y).
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decline in eGFR and increase in UACR in model 6, the sig-
nificant association between baseline UACR and LVMI
persisted. In addition, every 1 mL/min/1.73 m2/y decline
in eGFR was significantly associated with 1.05 g/m2 higher
LVMI at the end of follow-up (P ¼ .02). LVMI significantly
increased by 4.19 g/m2 in those with rate of UACR increase
of 1.07 mg/g/y compared to individuals with UACR rate
of increase of <0.14 mg/g/y (P ¼ .02), and although not
statistically significant, by 2.65 g/m2 in those with rate of
UACR increase of between 0.14 and 1.07 mg/g/y
(P ¼ .15). Other covariates positively associated with
LVMI were waist circumference (b ¼ 0.18; 95% confi-
dence interval [CI]: [0.04, 0.32]), SBP (b ¼ 0.29; 95%
CI: [0.18, 0.40]), and SBP change (b ¼ 0.25; 95% CI:
[0.15, 0.35]). No significant interactions were observed be-
tween age, gender, change in SBP, or change in DBP with
kidney biomarkers on LVMI. Analysis results remained un-
changed after excluding individuals with heart disease at
baseline (Table S2).
Sensitivity analysis using 2D-mode measurement of
LVMI yielded consistent results.
Left Ventricular Hypertrophy
The adjusted associations between kidney biomarkers
and LVH are summarized in Table 4. In the final model
(model 6), both baseline eGFR and baseline UACR were
significantly associated with LVH (eGFR: odds ratio
[OR] ¼ 0.97; 95% CI: [0.95, 0.99]; UACR: OR ¼ 1.37;
95% CI: [1.04, 1.80]). Rate of UACR increase group of
1.07 mg/g/y conferred a 2.17-time greater risk of LVH
(OR ¼ 2.17; 95% CI: [0.97–4.83]) using <0.14 mg/g/y
as the reference group. In contrast, there was no association
between rate of eGFR decline and LVH, albeit the direction
of association was similar to that of LVMI.
PWT and SWT
Table 5 shows the multivariate association of kidney
biomarkers with the outcomes of PWT and SWT. Higher
baseline UACR and greater rate of eGFR decline were
significantly associated with increase in PWT. Rate of
UACR increase between groups of 0.14 and 1.07 mg/g/y
and 1.07 mg/g/y both was associated with higher PWT
as compared with group of rate <0.14 mg/g/y. However,
baseline eGFR had no association with PWT. As for
SWT, both baseline UACR and rate of increase in
UACR were positively associated with SWT. In contrast,
no association was identified between baseline eGFR or
its rate of decline and SWT. Sensitivity analysis using
2D-mode measurements of PWT and SWT yielded consis-
tent results.
Table 5
Association of baseline and rate of increase in eGFR (mL/min/1.73 m2) and UACR (mg/g) with posterior wall thickness (cm) and septal
wall thickness (cm) (n ¼ 539) from multiple regression analysis
Variables Posterior Wall Thickness (M Mode) Septal Wall Thickness (M Mode)
b Coefficient (95% CI) P Value b Coefficient (95% CI) P Value
Baseline eGFR 0.0001 (0.0007, 0.0008) .83 0.0003 (0.0005, 0.0012) .44
Baseline UACR 0.0114 (0.0025, 0.0203) .013 0.0120 (0.0021, 0.0219) .018
Rate of decline in eGFR* 0.0075 (0.0132, 0.0019) .009 0.0010 (0.0072, 0.0053) .76
Rate of increase in UACRy .048 .019
<0.14 (Ref)
0.14–1.07 0.0260 (0.0028, 0.0492) .028 0.0285 (0.0028, 0.0542) .03
1.07 0.0232 (0.0011,0.0452) .039 0.0329 (0.0085, 0.0573) .008
Gender (female) 0.0320 (0.0548, 0.0092) .006 0.0362 (0.0614, 0.0109) .005
Waist circumference 0.0024 (0.0015, 0.0032) <.001 0.0022 (0.0013, 0.0032) <.001
Baseline SBP 0.0014 (0.0006, 0.0021) <.001 0.0015 (0.0007, 0.0023) <.001
SBP changez 0.0007 (0.0001, 0.0013) .022 0.0006 (0.0001, 0.0013) .098
ARB, angiotensin II receptor blocker; ACEI, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; DBP, diastolic
blood pressure; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic
blood pressure; UACR, urine albumin-to-creatinine ratio.
Note: Variables in the model were baseline eGFR, baseline UACR, rate of decline in eGFR, rate of increase in UACR, age, gender,
education, waist circumference, diabetes, heart disease, SBP, SBP change, DBP, DBP change, smoking, LDL, HDL, triglyceride, ACEI
or ARB use, CCB use, b-blocker use, diuretics use, and intervention group.
All models accounted for clustering effect by household as a random effect.
In addition to kidney function biomarkers, variables with P value < .05 for either outcomes were reported in the table.
* Rate of decline in eGFR ¼ (eGFR at year 7  eGFR at baseline)/duration of follow-up (in y).
yRate of increase in UACR ¼ (UACR at year 7  UACR at baseline)/duration of follow-up (in y).
zChange in SBP was calculated using SBP at year 7 minus baseline SBP.
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Discussion
Our study examining the association of markers of kidney
function and damage with LVMI among 539 hypertensive
individuals with near normal kidney function from the gen-
eral population in communities in Pakistan found that higher
baseline UACR, greater rate of increase in UACR, and
greater rate of decline in eGFR were strongly and indepen-
dently associated with higher LVMI at the 7-year follow-up.
Similar results were found for PWT and SWT, except that
rate of eGFR decline was not associated SWT. Higher base-
line UACR, lower baseline eGFR, and the rate of increase in
UACR of 1.07 mg/g/y versus <0.14 mg/g/y predicted
greater risk of LVH. Our findings based on the first study
of its kind in communities in South Asia have tremendous
clinical and public health implications for screening and
monitoring kidney markers, each offering prognostic infor-
mation for risk stratification of individuals at high risk of
adverse cardiac outcomes, especially in South Asians—a
population known to be at high risk of CVD.15,16
Our findings corroborate studies in other populations9–13
indicating that kidney dysfunction as a static measure or ev-
idence of progressive worsening over time predicted higher
LVMI. Presence of albuminuria has been shown to predict
future LVMI in individuals with hypertension.23,24 A reduc-
tion in microalbuminuria has been shown to be a significant
predictor of reduced chance of LVH regression.12 In addi-
tion, in a report by Bansal et al,11 decline in eGFR was
significantly associated with higher LVMI 10 years later
in a sample of 2410 black and white participants with base-
line eGFR >60 mL/min/1.73 m2. Furthermore, parallel
worsening of eGFR and albuminuria, compared to either
alone, has been associated with greater LVMI.24 Our study
extends previous research by evaluating dynamic change in
UACR and eGFR in combination for prediction of cardiac
abnormalities and to demonstrate independent long-term
effects of markers of both static and dynamic kidney dam-
age parameters on LVMI in hypertensive individuals in
low-income communities in South Asia.
It is important to highlight that in our study, change in
SBP was significantly correlated with baseline UACR,
rate of UACR increase, rate of eGFR decline, and LVMI.
However, the associations between markers of kidney dam-
age with LVMI were independent of baseline SBP and its
change over the follow-up. Few studies adjusted for change
in SBP when examining the effect of kidney dysfunction on
cardiac structure.11,13
It is also interesting to note that decline in eGFR was
associated with increase in PWT; however, its relationship
with SWT was not significant. This suggests the possibility
of eccentric left ventricular hypertrophy being associated
with reduced kidney function which has been reported
previously.25
The mechanisms linking kidney dysfunction to cardiac
abnormalities are still unclear. Traditional cardiovascular
risk factors at baseline such as hypertension, diabetes,
high cholesterol, and smoking do not entirely explain the
associations because they were controlled for in the anal-
ysis. Likewise, the multivariable analysis was adjusted for
greater decline in systolic BP among those without LVH
compared to those with LVH. In patients with chronic kid-
ney disease, anemia is a potential factor mediating the as-
sociation between markers of kidney dysfunction and
LVMI. Average eGFR was high in our population
(91 mL/min/1.73 m2) with only two subjects having an
eGFR of <30 mL/min/1.73 m2. Therefore, we believe
that low hemoglobin may not play a major role in the
observed associations. Albuminuria is theoretically related
to multiple pathophysiological processes including comor-
bidities, systemic inflammation, and endothelial dysfunc-
tion and is a marker of generalized cardiovascular
damage.26,27 Other possible factors could be overactivity
of the renin–aldosterone system and sympathetic tone and
alteration in mineral metabolism such as 1,25-
hydroxyvitamin D, parathyroid hormone, and fibroblast
growth factor 23,28–30 all of which are associated with pro-
gressive kidney dysfunction and contribute to the develop-
ment and worsening of cardiac damage.
There are limitations in the study. First, echocardiogra-
phy was not performed at baseline, and we were not able
to evaluate possible confounding by baseline LVMI. How-
ever, we accounted for the presence of known heart disease
in the main analysis. Further, sensitivity analysis after
exclusion of individuals with heart disease yielded consis-
tent results. Nevertheless, residual confounding by subclin-
ical structural change could not be controlled for
adequately. For this reason, it is not possible to establish
a cause-effect relationship in this study. However, our find-
ings do establish the predictive association of eGFR and
UACR with LVMI and LVH. Second, 40% of the original
COBRA cohort were available with echocardiographic
data for analysis at 7-year follow-up. The analytic sample
represents relatively healthier hypertensive individuals
with better kidney function and lower prevalence of heart
disease and diabetes than the general population in the ur-
ban communities of Pakistan. Consequently, we expect
higher associations would be found in individuals with
more adverse risk factor profile. However, studies else-
where have reported potential utility of eGFR and UACR
to the Framingham risk score as prognostic of CVD mortal-
ity in patients with advanced kidney disease.31 Thus, our
findings might be generalizable to most of the general pop-
ulation in the communities in South Asia and possibly
neighboring countries, but additional studies are required
in more representative samples of hypertensive individuals
with a wide spectrum risk profile. Third, history of hyper-
tension and legacy effect of uncontrolled BP were not ac-
counted for in the analysis. However, use of
antihypertensive medications is known to lead to LVH
regression.32 Fourth, we only measured kidney biomarkers
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at baseline and end of follow-up and thus can only exam-
ined the linear changes in kidney biomarkers over time.
Finally, LVMI measurements using MM and 2D echocar-
diographic imaging have limitations including operator-
dependent technical issues such as image quality and
beam positioning as well as the assumption of a uniform
geometric shape of the left ventricle. However, the sonog-
raphers performing imaging in our study were trained as
per ASE guidelines with good interrater reproducibility
measures.33
The main strengths of our study include a community-
based sample identified using door-to-door census in
South Asia and rigorous measurement procedures
enhancing generalizability of findings to public health set-
tings. Other major strengths include long follow-up dura-
tion, improved accuracy of glomerular filtration rate
estimate using a locally modified CKD-EPI creatinine
equation and IDMS calibrated serum creatinine, adjust-
ment for important confounders rarely considered in early
studies (eg, BP change and lipid profile), and high quality
echocardiographic imaging with sound reliability mea-
surements. In addition, results of sensitivity analysis using
2D imaging were consistent with MM, as were ancillary
analyses for association of all kidney biomarkers with
PWT and UACR with SWT. Thus, we believe our findings
are robust.
Our findings have tremendous implications for public
health and clinical practice especially in South Asian coun-
tries where CVD is the leading cause of mortality account-
ing for one-third of all deaths with tremendous economic
consequences.15
Point of care testing for kidney function is available
across a variety of primary care settings, including care
by trained health workers providing home health checks
and education in resource-constrained regions globally.34
The PREVEND Study in the Netherlands demonstrated
that lowering albuminuria can prevent heart failure.35 Our
results suggest that screening for both eGFR and UACR
at baseline and during follow-up should be evaluated for
risk stratification and subsequent prevention of future
LVH and CVD in South Asians with hypertension. Such
an approach is likely to be cost-effective especially in
resource-constrained settings where access to cardiac imag-
ing technologies is limited.
In conclusion, higher baseline albuminuria, lower base-
line eGFR, and their longitudinal worsening over 7 years
were significantly associated with higher LVMI or the
development of LVH among individuals with hypertension
in Pakistan. The findings suggest that both baseline
screening and follow-up monitoring eGFR and UACR
could potentially enhance cardiovascular risk stratification
for cardiac structural damage and subsequent CVD. Future
studies should consider both static and dynamic marker of
kidney dysfunction for risk stratification and prevention of
CVD.
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Table S1
Comparison of baseline characteristics between individuals in analytic sample and those excluded from the analysis
Variable n Analytic Sample (n ¼ 539) Excluded (n ¼ 802) P Value
Age, mean (SD) 50.9 (9.06) 55.9 (12.2) <.001
Female, n (%) 340 (63.1) 500 (62.3) .78
Education, n (%) <.001
Formal 358 (66.2) 429 (53.5)
Not formal 181 (33.6) 373 (46.5)
BMI (kg/m2, mean, SD) 1337 27.7 (5.0) 26.0 (5.5) <.001
SBP (mm Hg, mean, SD) 149.1 (22.6) 153.2 (25.6) .002
DBP (mm Hg, mean, SD) 92.9 (12.3) 93.1 (13.6) .78
ARB or ACEI, n (%) 71 (13.2) 112 (14.0) .68
b-Blocker, n (%) 119 (22.1) 153 (19.1) .18
CCB, n (%) 51 (9.5) 78 (9.7) .87
Diuretics, n (%) 12 (2.2) 27 (3.4) .22
Diabetes, n (%) 1279 129 (23.9) 241 (32.6) <.001
Heart disease, n (%) 1334 64 (11.9) 119 (14.8) .11
Smoking, n (%) <.001
Never 333 (61.8) 401 (50.0)
Current or past 206 (38.2) 401 (50.0)
LDL (mg/dL, mean, SD) 1271 120.4 (32.9) 118.9 (32.4) .40
HDL (mg/dL, mean, SD) 1271 40.3 (10.3) 40.9 (10.7) .31
Triglyceride (mg/dL, mean, SD) 1271 179.4 (102) 165 (84.1) .007
eGFR (mL/min/1.73 m2, mean, SD) 1271 91.0 (15.9) 84.2 (20.9) <.001
UACR (mg/g, median, IQR) 1272 6.2 (3.9, 11.3) 6.9 (4.4, 19.7) <.001
Intervention group, n (%) <.001
No intervention 137 (25.4) 189 (23.6)
GP only 107 (19.9) 228 (28.4)
HHE only 129 (23.9) 219 (27.3)
GP and HHE 166 (30.8) 166 (20.7)
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CCB, calcium channel
blocker; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; GP, general practitioner; HDL, high-density lipoprotein;
HHE, home health education; IQR, interquartile range; LDL, low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation;
UACR, urine albumin-to-creatinine ratio.
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Table S2
Association of baseline and rate of increase in eGFR (mL/min/
1.73 m2) and UACR (mg/g) with LVMI (g/m2) in individuals
without heart disease (n ¼ 475) from multiple regression
Variables Without Heart Disease N ¼ 475
b-Coefficient 95% (CI) P Value
Baseline eGFR 0.12 (0.24, 0.01) .06
Baseline UACR 2.29 (0.80, 3.77) .003
Gender (female) 1.96 (5.90, 1.98) .33
BMI 0.31 (0.02, 0.65) .06
Baseline SBP 0.30 (0.18, 0.42) <.001
SBP change* 0.26 (0.16, 0.36) <.001
Rate of increase in eGFRy 1.04 (2.00, 0.09) .03
Rate of increase in UACRz .05
<0.14 Reference
0.14–1.07 2.86 (1.05, 6.77) .15
1.07 4.60 (0.87, 8.33) .02
BMI, body mass index; CI, confidence interval; eGFR, estimated
glomerular filtration rate; LVMI, left ventricular mass index; SBP,
systolic blood pressure; UACR, urine albumin-to-creatinine ratio.
Analysis was based on model 6 including all covariates and ac-
counted for clustering effect by household as a random effect.
* Change in SBP was calculated using SBP at year 7 minus
baseline SBP.
yRate of increase in eGFR ¼ (eGFR at year 7  eGFR at base-
line)/duration of follow-up (in y).
zRate of increase in UACR ¼ (UACR at year 7  UACR at
baseline)/duration of follow-up (in y).
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